Related Experiment Video

Updated: Jun 10, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Protein kinase C - possible therapeutic target to treat cardiovascular diseases

Yamini S Bynagari-Settipalli1, Ramya Chari, Laurie Kilpatrick

  • 1Department of Physiology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.

Cardiovascular & Hematological Disorders Drug Targets
|August 4, 2010
PubMed

Insights

Protein Kinase C (PKC) isoforms play critical roles in cardiovascular diseases. Targeting specific PKC isoforms offers a promising therapeutic strategy for treating conditions like atherosclerosis and diabetes.

Area of Science:

  • Cardiovascular biology and pharmacology
  • Molecular mechanisms of cardiovascular disease

Background:

  • Cardiovascular diseases (CVDs) are a leading cause of global mortality, with thrombosis exacerbating conditions like atherosclerosis and diabetes.
  • Protein Kinase C (PKC) enzymes are crucial for cardiovascular cell function, but their roles can be complex and context-dependent.

Purpose of the Study:

  • To review the specific roles of individual Protein Kinase C (PKC) isoforms in various cardiovascular diseases.
  • To detail the mechanisms and therapeutic potential of specific PKC isoform modulators for cardiovascular conditions.

Main Methods:

  • Review of existing literature on PKC isoform function in cardiovascular cells.
  • Analysis of studies using pharmacological inhibitors/activators and gene knockout models for PKC isoforms.
  • Examination of data from animal models and human subjects evaluating PKC modulators.

Main Results:

  • PKC isotypes exhibit context-specific activities, with some having opposing roles in different cardiovascular cell types.
  • Structural differences among PKC isoforms allow for the development of isoform-specific modulators.
  • Targeting specific PKC isoforms holds potential for enhancing protective effects while mitigating adverse ones.

Conclusions:

  • Understanding the distinct functions of each PKC isoform is key to developing effective cardiovascular therapies.
  • Modulating specific PKC isoforms presents a viable strategy to treat cardiovascular diseases like atherosclerosis and diabetes.
  • Further research into PKC isoform modulators could lead to novel treatments for myocardial infarction and stroke.

More Related Videos

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...